Kiyohide Nunoi
St. Mary's Hospital
Kurume, Japan
Kurume, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Basal insulin secretion capacity predicts the initial response and maximum levels of beta-hydroxybutyrate during therapy with the sodium-glucose co-transporter-2 inhibitor tofogliflozin, in relation to weight loss.
Journal: Diabetes, obesity & metabolism
Published: July 10, 2019
Development of the Daily Time Management Scale for Use by Working People with Type 2 Diabetes.
Journal: Japan journal of nursing science : JJNS
Published: November 09, 2018
Renal effects of a sodium-glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status.
Journal: Diabetes, obesity & metabolism
Published: October 31, 2018
Effects of sodium-glucose cotransporter 2 inhibitor, tofogliflozin, on the indices of renal tubular function in patients with type 2 diabetes.
Journal: Endocrinology, diabetes & metabolism
Published: January 23, 2018
Onset of reversible flaccid quadriplegia during treatment of thyrotoxic crisis.
Journal: Internal medicine (Tokyo, Japan)
Published: March 10, 2015
Simultaneous occurrence of type 1 diabetes mellitus and Graves' disease: a report of two cases and a review of the literature.
Journal: Internal medicine (Tokyo, Japan)
Published: November 19, 2013
Isolated adrenocorticotropin deficiency associated with painless thyroiditis: a case report and review of the literature.
Journal: The Kurume medical journal
Published: January 01, 2012
Randomized controlled trial of single-agent glimepiride and pioglitazone in Japanese patients with type 2 diabetes: A comparative study.
Journal: Journal of diabetes investigation
Published: October 07, 2011
Showing 1-9 of 9
Last Updated: 09/26/2026